Newborn Screening Expansion through Metabolomics: Evaluating Benefits, Harms, and Decision Frameworks for Public Health

Read full text Summarise with VIRAT
Authors: Serunjogi Ruth
Cited by: 0
References: 16

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Newborn screening is a cornerstone of preventive public health, enabling the early identification of congenital and metabolic disorders for which timely intervention can substantially reduce morbidity and mortality. Advances in metabolomics now present an opportunity to expand newborn screening beyond current targeted assays, allowing the simultaneous measurement of hundreds of metabolites from dried blood spots and thereby broadening disease coverage and improving diagnostic accuracy. This paper critically evaluates the expansion of newborn screening through metabolomics, examining its scientific rationale, methodological foundations, anticipated public health benefits, and potential harms. We assess analytical and biostatistical considerations, including assay validation, data interpretation, false-positive rates, incidental findings, and long-term outcome uncertainty. Particular attention is given to health equity, resource use, sustainability, and the ethical, legal, and governance challenges associated with large-scale population screening. Drawing on established benefit–harm assessment models and public health decision frameworks, the paper outlines criteria for policy adoption and responsible implementation. We conclude that metabolomics-based expansion of newborn screening holds significant promise for improving population health outcomes, but its adoption must be guided by rigorous evidence, transparent governance, stakeholder engagement, and equity-focused implementation strategies to ensure that benefits clearly outweigh harms at the population level. Keywords: Newborn screening, Metabolomics, Public health decision frameworks, Benefit–harm assessment and Health equity

Fields of Study & Subjects

Metabolism and Genetic Disorders Metabolomics and Mass Spectrometry Studies Genomics and Rare Diseases

Publication details

Journal / source
IAA Journal of Biological Sciences
Volume
14
Issue
1
Pages
114–124
Publication date
22 March 2026
Language
EN